Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05168618 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Study acronym: AtezoCab
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 5, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion pushed from May 2026 to Jul 2026v11
  2. Start date: Mar 11, 2022 to Mar 29, 2022 Eligibility criteria expanded, about 230 words · Secondary endpoints revised (5) · Collaborators: 1 to 2 · 1 morev10 Show 4 more changesShow less
    • Eligibility criteria expanded, about 230 words
    • Secondary endpoints revised (5)
    • Collaborators: 1 to 2
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Apr 2025 to May 2026v9
  4. Primary completion date: Jan 2025 to Apr 2025v8
  5. Eligibility criteria expanded, about 13 wordsv7 See this version in full on ClinicalTrials.gov ↗
Show 5 earlier versionsHide 5 earlier versions
  1. Re-verified, no change to tracked fieldsv6
  2. Secondary endpoints: details revised at 1 of 5 entries Eligibility criteria expanded, about 5 wordsv5 Show 1 more changeShow less
    • Eligibility criteria expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 2022 to Mar 11, 2022 · Site details revisedv4 Show 2 more changesShow less
    • Start date changed from estimate of Mar 2022 to Mar 11, 2022
    • Site details revised
  4. Eligibility criteria expanded, about 3 wordsv3 See this version in full on ClinicalTrials.gov ↗
  5. Start date: Jan 15, 2022 to Mar 2022 Primary completion date: Jan 15, 2025 to Jan 2025 · Completion date: Jan 15, 2027 to Jan 2027v2 Show 2 more changesShow less
    • Primary completion date: Jan 15, 2025 to Jan 2025
    • Completion date: Jan 15, 2027 to Jan 2027
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and atezolizumab may kill more tumor cells in patients with metastatic castrate-resistant prostate cancer.
Trial Details
NCT Number NCT05168618
Lead Sponsor University of Utah
Collaborators: National Cancer Institute (NCI), Huntsman Cancer Institute
Conditions Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov